X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

AbbVie, University of Chicago team collaborative on cancer innovation efforts

Yuvraj_pawp by Yuvraj_pawp
20th April 2016
in Drug Development

The University of Chicago and AbbVie a global biopharmaceutical company, have entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in oncology at both organizations.

 

The joint strategic research agreement between AbbVie and the University of Chicago is designed to encourage and strengthen collaboration among researchers. Initially, both organizations will work together to advance research in several areas of oncology, which could include, among others, breast, lung, prostate, colorectal and hematological cancer. Research projects are chosen by a joint steering committee, comprised of representatives from each organization. AbbVie also gains an option for an exclusive license to certainUniversity of Chicago discoveries made under the agreement.

 

Kenneth S. Polonsky, MD, executive vice president for medical affairs at the University of Chicago and dean of the Biological Sciences Division and Pritzker School of Medicine said,University of Chicago researchers and clinicians have worked closely with AbbVie scientists in areas such as immunology and oncology for some time,This agreement adds depth to that established and productive collaboration. The increased level of interaction should speed progress in medical care, beginning with cancer patients.

 

As part of the agreement, AbbVie will provide funding for the collaboration that may be used for purposes including preclinical research, clinical trials and possible future programs at the University resulting from this partnership. The overall collaborative efforts will provideUniversity of Chicago physicians and scientists with the opportunity to participate in AbbVie-sponsored clinical trials, access to new therapies developed by AbbVie for use in preclinical research funded under the collaboration, as well as opportunities to work closely with AbbVie’s research and development teams to promote scientific knowledge exchange.

 

Gary Gordon, M.D., Ph.D., vice president, oncology clinical development, AbbVie said, advancements in oncology – both at the basic science and clinical levels – are happening faster and more broadly every day,collaborating closely with the scientists and clinicians at theUniversity of Chicago allows us to expand our own research efforts even further to benefit patients.”

 

As part of the collaborative agreement, researchers from the University of Chicago and AbbVie will participate in an annual symposium that brings together scientists from both institutions to discuss research and evaluate potential new projects.

 

cancer specialist Everett Vokes, MD, professor and chairman of medicine at the University of Chicago said , this is a wonderful opportunity for our investigators to join forces with a leader in oncology and new drug development, accelerate the pace of discovery and deliver clinical benefits to our patients,this will support pre-clinical research, give our physician-scientists earlier access to drugs in the AbbVie pipeline and lay the groundwork for further interaction and collaboration.

 

AbbVie also holds a membership to the Chicago Innovation Exchange, a hub for multidisciplinary collaborations and support for business startup activities and an observer seat at meetings of the University of Chicago Innovation Fund Advisory Committee, which provides guidance to the Innovation Fund, a $20 million investment fund focusing on commercializing early stage research and supporting emerging companies at the University. The Innovation Fund is managed by the Chicago Innovation Exchange in partnership withUChicagoTech and the Polsky Center for Entrepreneurship & Innovation.

 

Collaborative efforts also provide AbbVie researchers with access to data commons technology developed by the Center for Data Intensive Science at the University of Chicago and the core technical team that is developing the technology. This novel platform powers several large-scale resources for the research community, including the National Cancer Institute Genomic Data Commons – one of the world’s largest storage, analysis and distribution systems for cancer genomics data.

 

About AbbVie

 

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

About the University of Chicago

 

The University of Chicago advances ideas and innovations that enrich human life. The Biological Sciences Division (BSD) at the University is home to both the basic biological sciences and all clinical disciplines, encouraging strong interdisciplinary collaborative and innovative approaches to the study of complex problems. The BSD is also home to The University of Chicago Medicine Comprehensive Cancer Center, an internationally respected leading center in cancer care and research, including conducting all phases of cancer clinical trials to develop new therapies.

Previous Post

Merck Receives Breakthrough Therapy Designation from U.S. FDA for KEYTRUDA in Classical Hodgkin Lymphoma (cHL)

Next Post

AstraZeneca transforms drug discovery with new integrated genomics approach

Related Posts

development of new antibiotics
Drug Development

EMA guidance supports development of new antibiotics

30th May 2022
Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows
Manufacturing

Commercial Success In New Biopharmaceutical Innovation Era

21st May 2022
Manufacturing

Proteros and AstraZeneca Boost Collaboration Agreement

18th May 2022
Conver to wp
Drug Development

AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

18th May 2022
Drug Imagent For Therapeutic Platform
Drug Development

Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

18th May 2022
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
Drug Development

Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

6th May 2022
Next Post

AstraZeneca transforms drug discovery with new integrated genomics approach

Latest News

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In